AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 4.93 |
|---|---|
| Change | +0.160 3.245% |
| 52 W H/L (in USD) | 5.700/2.600 |
| EBITDA (in USD) | -69.436M |
| PE Ratio | -- |
| Volume | 1962099 |
| Diluted Eps TTM | -0.37 |
| Total Assets (in USD) | 177.564M |
|---|---|
| Total Liabilities (in USD) | 37.192M |
| Revenue TTM (in USD) | 0.001M |
| Cash (in USD) | 26.585M |
| Market Cap (in USD) | 564.502 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -28.991M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047
(512) 614-1848
Employees: 37
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Matthew Pauls | Chairman & CEO | 1971 |
| 2. | Mr. David L. Lowrance CPA | CFO & Sec. | 1968 |
| 3. | Ms. Kate McCabe | Sr. VP of Legal Affairs | NA |
| 4. | Ms. Anne Erickson | Sr. VP & Head of Global Bus. Operations | NA |
| 5. | Brian Maurer | Head of Clinical Operations | NA |
| 6. | Mr. Charles LaPree | Sr. VP of Global Regulatory Affairs & Quality Assurance | NA |
| 7. | Dr. Peter Clarke Ph.D. | Exec. VP of Global Technical Operations | 1960 |
| 8. | Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer | 1951 |
| 9. | Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 1971 |
| 10. | Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.620 1.470% | 41.67 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.440 3.453% | 41.72 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-10.060 2.257% | 447.27 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-14.530 2.358% | 619.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -38.15M | -43.014M | -49.615M | -78.173M | -70.027M |
| Minority Interest | - | - | - | - | - |
| Net Income | -38.946M | -45.296M | -51.097M | -105.025M | -61.516M |
| Selling General Administrative | 10.929M | 12.35M | 14.264M | 13.081M | 10.654M |
| Gross Profit | - | -0.136M | 0.257M | - | 0M |
| Reconciled Depreciation | 0.167M | 0.367M | 0.693M | 1.01M | 0.526M |
| Ebit | -38.839M | -41.477M | -49.3M | -79.025M | -26.661M |
| Ebitda | -37.876M | -40.266M | -47.714M | -25.01M | -26.135M |
| Depreciation And Amortization | 0.963M | 1.211M | 1.586M | 54.015M | 0.526M |
| Operating Income | -38.839M | -41.477M | -49.3M | -79.025M | -70.045M |
| Other Operating Expenses | 38.043M | 40.633M | 48.664M | 52.173M | 48.353M |
| Interest Expense | 0.088M | 2.282M | 1.482M | -0.07M | 0.011M |
| Tax Provision | - | - | - | 0M | -8.511M |
| Interest Income | - | - | - | 0.361M | 0.018M |
| Net Interest Income | -0.088M | -2.282M | -1.482M | -0.07M | 0.011M |
| Income Tax Expense | 0.796M | 2.282M | 1.482M | 26.852M | -8.511M |
| Total Revenue | 0M | 0M | 0.257M | 0M | 0M |
| Total Operating Expenses | 38.043M | 40.633M | 48.664M | 52.173M | 48.353M |
| Cost Of Revenue | - | 0.136M | - | - | 0M |
| Total Other Income Expense Net | 0.689M | -1.537M | -0.315M | 0.852M | -21.692M |
| Net Income From Continuing Ops | -38.15M | -43.014M | -49.615M | -78.173M | -61.516M |
| Net Income Applicable To Common Shares | - | -43.014M | -49.615M | -78.173M | -61.516M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 177.564M | 139.777M | 176.598M | 97.745M | 136.203M |
| Intangible Assets | 10.96M | 10.656M | 11.274M | 12.218M | 11.111M |
| Other Current Assets | 2.623M | 0.071M | 3.829M | 2.933M | 2.306M |
| Total Liab | 37.192M | 31.999M | 32.1M | 33.362M | 34.505M |
| Total Stockholder Equity | 140.372M | 107.778M | 144.498M | 64.383M | 101.698M |
| Other Current Liab | 6.95M | 4.469M | 4.749M | 5.4M | 5.031M |
| Common Stock | 0.14M | 0.116M | 0.116M | 0.055M | 0.052M |
| Capital Stock | 0.14M | 0.116M | 0.116M | 0.055M | 0.052M |
| Retained Earnings | -393.369M | -338.671M | -300.521M | -257.507M | -207.892M |
| Good Will | - | - | - | - | 0M |
| Other Assets | 0M | - | - | 12.468M | 11.111M |
| Cash | 26.585M | 52.1M | 34.012M | 22.88M | 49.804M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 10.597M | 5.867M | 14.66M | 8.174M | 10.88M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | 0.153M | -25.958M | -8.221M | 2.403M | -24.252M |
| Short Term Debt | 0.143M | 0.064M | 8.468M | 0.179M | 2.44M |
| Short Long Term Debt | - | - | 8.333M | - | 2M |
| Short Long Term Debt Total | 26.738M | 26.142M | 25.791M | 25.283M | 25.552M |
| Other Stockholder Equity | 533.872M | 446.938M | 444.898M | 320.893M | 309.555M |
| Property Plant Equipment | - | - | 0.324M | 0.156M | 0.352M |
| Total Current Assets | 165.947M | 128.954M | 165M | 85.121M | 124.067M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 135.734M | 73.776M | 127.159M | 59.308M | 71.957M |
| Net Receivables | 1.005M | 0.954M | 1.144M | 1.695M | 1.617M |
| Long Term Debt | 26.348M | 26.078M | 17.323M | 25.104M | 23.112M |
| Inventory | 0M | 2.053M | -1.144M | -1.695M | -1.617M |
| Accounts Payable | 3.504M | 1.334M | 1.443M | 2.595M | 3.409M |
| Accumulated Other Comprehensive Income | -0.271M | -0.605M | 0.005M | 0.942M | -0.017M |
| Non Currrent Assets Other | 0.387M | 0.116M | 0.251M | 0.25M | 0.673M |
| Non Current Assets Total | 11.617M | 10.823M | 11.598M | 12.624M | 12.136M |
| Capital Lease Obligations | 0.143M | 0.064M | 0.135M | 0.179M | 0.44M |
| Long Term Debt Total | - | - | - | 25.104M | 23.112M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 52.645M | -69.456M | 98.43M | 138.833M | -13.478M |
| Total Cashflows From Investing Activities | - | -69.456M | 9.053M | 15.74M | -13.619M |
| Total Cash From Financing Activities | 0.087M | 120.806M | 3.689M | 54.908M | 55.193M |
| Net Income | -38.15M | -43.014M | -49.615M | -78.173M | -61.516M |
| Change In Cash | 18.088M | 11.132M | -26.924M | 25.503M | 2.18M |
| Begin Period Cash Flow | 34.012M | 22.88M | 49.804M | 24.301M | 22.121M |
| End Period Cash Flow | 52.1M | 34.012M | 22.88M | 49.804M | 24.301M |
| Total Cash From Operating Activities | -34.554M | -40.081M | -39.836M | -45.123M | -39.275M |
| Depreciation | 0.167M | 0.367M | 0.693M | 1.01M | 0.526M |
| Other Cashflows From Investing Activities | - | - | -89.33M | -122.945M | -13.478M |
| Dividends Paid | - | - | -2.12M | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | -0.003M | -0.078M | 2.12M | 54.949M | 46.355M |
| Other Cashflows From Financing Activities | 26.438M | -1.347M | 1.913M | 0.11M | 9.442M |
| Capital Expenditures | 0.009M | 0.057M | 3.294M | 0.148M | 0.141M |
| Change In Working Capital | 0.96M | -2.846M | -1.705M | 0.847M | 2.446M |
| Other Non Cash Items | 0.428M | 0.449M | 5.903M | 0.774M | 22.589M |
| Free Cash Flow | -34.563M | -40.138M | -43.13M | -45.271M | -39.416M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Jennison Health Sciences Equity | 2 years ago | 5583192 |
| 2. | PGIM Jennison Health Sciences Z | 2 years ago | 4436034 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 3936294 |
| 4. | iShares Russell 2000 ETF | 2 years ago | 2113225 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1402063 |
| 6. | UTM IM GBP AXA Framlington Biotech | 2 years ago | 1275590 |
| 7. | Fidelity Small Cap Index | 2 years ago | 926388 |
| 8. | iShares Russell 2000 Value ETF | 2 years ago | 790666 |
| 9. | DWS ESG Biotech LC | 2 years ago | 600013 |
| 10. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 555100 |
| 11. | Fidelity Extended Market Index | 2 years ago | 554339 |
| 12. | iShares Biotechnology ETF | 2 years ago | 478575 |
| 13. | Vanguard Russell 2000 ETF | 2 years ago | 338797 |
| 14. | Fidelity Nasdaq Composite ETF | 2 years ago | 310945 |
| 15. | Acuitas US Microcap Strategy | 2 years ago | 307569 |
| 16. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 281000 |
| 17. | NT R2000 Index Fund - NL | 2 years ago | 250140 |
| 18. | NT R2000 Value Index Fund - NL | 2 years ago | 245991 |
| 19. | Wellington CIF II SMID Cap Research S3 | 2 years ago | 236064 |
| 20. | BlackRock Extended Mkt Composite | 2 years ago | 225632 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | NEA Management Company, LLC | 2 years ago | 24471264 |
| 2. | Bain Capital Life Sciences Investors, LLC | 2 years ago | 14565457 |
| 3. | TCG Crossover Management, LLC | 2 years ago | 10000000 |
| 4. | Jennison Associates LLC | 2 years ago | 8841971 |
| 5. | Adage Capital Partners Gp LLC | 2 years ago | 8287930 |
| 6. | BlackRock Inc | 2 years ago | 7261530 |
| 7. | Vanguard Group Inc | 2 years ago | 6063620 |
| 8. | HHG PLC | 2 years ago | 2563620 |
| 9. | Farallon Capital Management, L.L.C. | 2 years ago | 2394299 |
| 10. | Sofinnova Ventures | 2 years ago | 2347261 |
| 11. | Geode Capital Management, LLC | 2 years ago | 2326873 |
| 12. | Vivo Capital, LLC | 2 years ago | 2088323 |
| 13. | SUPERSTRING CAPITAL MANAGEMENT LP | 2 years ago | 2065144 |
| 14. | Wellington Management Company LLP | 2 years ago | 2060173 |
| 15. | State Street Corporation | 2 years ago | 1768053 |
| 16. | Nantahala Capital Management, LLC | 2 years ago | 1737410 |
| 17. | Ghost Tree Capital, LLC | 2 years ago | 1600000 |
| 18. | Altium Capital Management, LP | 2 years ago | 1333000 |
| 19. | AXA SA | 2 years ago | 1330435 |
| 20. | Affinity Asset Advisors, LLC | 2 years ago | 1150000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...